Kyle Fletcher - Jul 13, 2022 Form 3 Insider Report for Celularity Inc (CELU)

Role
General Counsel
Signature
/s/ Keary Dunn, Attorney-in-Fact
Stock symbol
CELU
Transactions as of
Jul 13, 2022
Transactions value $
$0
Form type
3
Date filed
7/15/2022, 08:03 PM
Next filing
Nov 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CELU Class A Common Stock 33.1K Jul 13, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CELU Stock Option (Right to Buy) Jul 13, 2022 Class A Common Stock 22.7K $2.87 Direct F2
holding CELU Stock Option (Right to Buy) Jul 13, 2022 Class A Common Stock 11.4K $3.88 Direct F2
holding CELU Stock Option (Right to Buy) Jul 13, 2022 Class A Common Stock 34.9K $3.70 Direct F3
holding CELU Stock Option (Right to Buy) Jul 13, 2022 Class A Common Stock 26.3K $8.71 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan). Each RSU represents the right to receive one share of the Issuer's Class A common stock. The RSUs underlying this award vest and become exercisable over a four-year period, with 25% vesting on the one-year anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.
F2 These options were granted under the Issuer's Amended and Restated 2017 Equity Incentive Plan (the "2017 Plan") assumed in the business combination and 100% of the shares subject to the stock option are fully vested and exercisable as of the date hereof.
F3 This option was granted under the 2017 Plan and vests and becomes exercisable over a four-year period, with 25% of the option vesting on the one-year anniversary of the grant date, and the remainder vesting in equal monthly installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.
F4 This option was granted under the 2021 Plan and vests and becomes exercisable over a four-year period, with 25% of the option vesting on the one-year anniversary of the grant date, and the remainder vesting in equal monthly installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney